D.A. POVALYAEVA¹, V.V. EGOROV^1,2, G.P. SMOLYAKOVA^1,2, L.P. DANILOVA^1,2

¹Khabarovsk branch of the S. Fyodorov Eye Microsurgery Federal State Institution, 211 Tikhookeanskaya Str., Khabarovsk, Russian Federation, 680033

²Postgraduate Institute for Public Health Workers, 9 Krasnodarskaya Str., Khabarovsk, Russian Federation, 680009

 Povalyaeva D.A. — ophthalmologist of the Department of Complex Rehabilitation Treatment, tel. (4212) 22-51-21, e-mail: naukakhvmntk@mail.ru

Egorov V.V. — D. Med. Sc., Professor, Director, Head of the Department of Ophthalmology, tel. (4212) 22-51-21, e-mail: khvmntk@mail.ru

Smolyakova G.P. — D. Med. Sc., Professor, ophthalmologist of the Clinical-expert Department, Professor of the Ophthalmology Department, tel. (4212) 22-51-21, e-mail: naukakhvmntk@mail.ru

Danilova L.P. — Head of the Department of Complex Rehabilitation Treatment, Assistant Lecturer of the Ophthalmology Department, tel. (4212) 22-51-21, e-mail: naukakhvmntk@mail.ru

 Evaluation was carried out of the clinical effectiveness of the complex treatment system of optic neuritis (ON), including immunopharmacotherapy methods, in patients with herpes-virus infection (HVI). The clinical study involved 35 people (35 eyes) with acute ON associated with HVI. The treatment regimen for all patients included 10 days of Dexamethasone solution, Emoxypine 1% 0.5 ml, and Dicynone 12.5% 0.5 ml through irrigation system implanted in the retrobulbar space, in combination with the neuroprotective drugs (Picamilon and Semax). Depending on the features of immunotherapy, all patients were divided into 2 groups. The first group consisted of 17 patients, whose treatment in addition to the above included intravenous infusions of 6 mg Polyoxidonium and muscle injections of Cycloferon. The second group consisted of 18 patients whose etiotropic immunotherapy consisted of combination of Polyoxidonium, Cycloferon and endonasal electrophoresis of 0.25% solution of Derinat. The duration of immunotherapy was 10-12 days. The analysis of the obtained data showed the more significant positive dynamics in the clinical course of ON in patients of the 2nd group of observation, who simultaneously received a complex of 3 immunotropic drugs in comparison with group 1, in the treatment of which we used combination of Polyoxidonium with Cycloferon without Derinat. The elaborated method of etiotropic and pathogenetic immunotherapy, represented by the combination of Polyoxidonium, Cycloferon and Derinat, with herpes-associated ON, allows to shorten the time of recovery and improve the functional results of treatment in the absence of recurrence of the disease within 1 year of observation.

Key words: optic neuritis, herpes-virus infection, corticosteroid therapy, immunotherapy.

References

1. LibmanS.,Shakhova E.V.Blindness anddisability due to eye pathology in Russia.Annals of Ophthalmology, 2006, no. 1, pp. 35-37. (in Russ.).
2. Neroev V.V., Karlova I.Z., Guseva R.M. et al. Pulse-therapy in the treatment of optic neuritis in multiple sclerosis. Annals of Ophthalmology, 2003, no. 5, pp. 28-30. (in Russ.).
3. Kalyuzhin O.V., Dikinov Z.H., Evsegneeva I.V. Immune mechanisms of experimental uveoretinitis. Kursk scientific-practical journal “Man and his health”, 2011, no. 1, pp. 153-159. (in Russ.).
4. Povalyaeva D.A., Egorov V.V., Smoliakova G.P., Danilova L.P., Emanova L.P. Clinical and immunological aspects of pathogenesis of infectious-associated optic neuritis. Modern technologies in ophthalmology, 2016, no. 4, pp. 177-180. (in Russ.).
5. Povalyaeva D.A., Egorov V.V., Smoliakova G.P., Danilova L.P., Emanova L.P. Results of study of etiological structure of idiopathic optic neuritis. Modern technologies in ophthalmology, 2016, no. 2, pp. 186-191. (in Russ.).
6. Didkovskii N.A., Malashenkova I.K., Tanasova A.N. et al. Herpesvirus infection: clinical implications and principles of therapy. Russian Medical Journal, 2004, no. 7, pp. 459. (in Russ.).
7. Klimov V.V., Cherevko N.A., Denisov A.A., Kologrivova E.N. Clinical immunology and allergology. Teaching manual, 2008, pp. 47-50. (in Russ.).
8. Chernakova G.M., Arzhimatova1 G.Sh., Kleshcheva E.A., Semenova T.B. Ophthalmoherpes: etiology, clinical features and therapy perspectives, 2015, 1-2, pp. 61-65. (in Russ.).
9. Isakov V.A., Rybalkin S.B., Romantsov M.G. Herpesvirus infection. Guidelines for doctors, 2006. 96 p. (in Russ.).
10. RU patent 2320300. Complex therapy method for treating optical neuritis cases. Danilova L.P., Smoliakova G.P., Emanova L.P. March 27, 2008; Bul. 9. 5 p. (in Russ.).
11. Povalyaeva D.A., Egorov V.V., Smoliakova G.P., Danilova L.P., Emanova L.P. Complex therapy of acute idiopathic optic neuritis. Modern technologies in ophthalmology, 2015; no. 2(6), pp. 161-163. (in Russ.).
12. Arvin A., Campadelli-Fiume G., Mocarski E. et al. Human herpesviruses: Biology, Therapy, and immunoprophylaxis, 2007. 1048 p.
13. Stirmanova E.R. The use of new eye drops Derinat in the complex therapy of herpetic keratitis (experimental and clinical study): Med.Sc.D. Dissertation, 2012. 105 p. (in Russ.).
14. Ishberdina L.Sh. Combined Cycloferon usage in patients with chorioretinitis. Clinical Ophthalmology, 2007, no. 1. 5 p. (in Russ.).
15. Isakov V.A., Ermolenko D.K., Goncharov S.B., Ermolenko K.D. Experience of using cycloferon in therapy of papillomavirus infection. Russian Medical Journal, 2009, no. 16, 1035 (in Russ.).
16. Marvanova Z.R. Clinical and immunological prognosis and corrective therapy with cycloferon of herpetic keratitis: Abstract of Med.Sc.D. Dissertation, 2003. 23 p. (in Russ.).
17. Kaplina E.N., Bazhanova N.O. Application of Derinat in ophthalmology. Teaching manual for doctors, 2008. 32 p. (in Russ.).
18. Komogorova E.E. Peculiarities of cellular immunity indices in patients with different forms of pulmonary tuberculosis and effect on these indices of Polyoxidonium: Abstract of Med.Sc.D. Dissertation, 2004. 23 p. (in Russ.)
19. Varfolomeeva M.I., Pinegin B.V. Rationale for use of Polyoxidonium for treatment and prevention of acute respiratory viral infection. Difficult patient, 2011, vol. 9, no. 6, pp. 38-42. (in Russ.).
20. Pikamilon – metabolic cerebrovascular and nootropic. Applicationinmedicalpractice, 2002. 48 p. (in Russ.).